Physician profile
Dallas Wright
NPI 1841776333
$3,935.20
in general payments reported to CMS, 2019-2025
46 companies · $2,612 in 2025
The $2,612 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.43 · 2023: $116 · 2024: $1,190 · 2025: $2,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,725.78 |
| Education | $192.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $501.78 | 2024-2025 | |
| Janssen Biotech, INC. | $230.47 | 2024-2025 | Imbruvica, Rybrevant, Darzalex |
| Astrazeneca Pharmaceuticals Lp | $229.87 | 2024-2025 | Calquence, Tagrisso, Imfinzi |
| Eisai INC. | $215.01 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $180.00 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Celgene Corporation | $172.17 | 2024-2025 | Reblozyl, Pomalyst |
| Abbvie INC. | $158.96 | 2024-2025 | |
| Seagen INC. | $130.29 | 2023-2025 | Adcetris |
| Glaxosmithkline, LLC. | $127.88 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Regeneron Healthcare Solutions, INC. | $126.41 | 2024-2025 | Libtayo |
| Pfizer INC. | $119.83 | 2024-2025 | |
| Tersera Therapeutics LLC | $100.62 | 2024-2025 | Xermelo, Zoladex |
| Gilead Sciences, INC. | $99.94 | 2024-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $94.92 | 2024-2025 | Opdualag, Opdivo, Krazati |
| Beone Medicines USA, INC. | $88.62 | 2025 | Tevimbra, Brukinsa |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $87.81 | 2022-2025 | Enhertu |
| Taiho Oncology, INC. | $85.31 | 2024-2025 | |
| Puma Biotechnology, INC. | $77.78 | 2024-2025 | |
| Array Biopharma INC | $77.72 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Aveo Pharmaceuticals, INC. | $72.05 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.14 | 2024-2025 | Ninlaro, Alunbrig |
| Incyte Corporation | $69.38 | 2024-2025 | Jakafi, Pemazyre, Monjuvi |
| Servier Pharmaceuticals LLC | $65.32 | 2024-2025 | |
| Sobi, INC | $63.55 | 2024-2025 | |
| Pharmaessentia USA Corporation | $60.11 | 2024-2025 | Besremi |
| Exelixis INC. | $59.66 | 2024-2025 | Cabometyx |
| Genmab U.S., INC. | $48.80 | 2024-2025 | Epkinly |
| Emd Serono, INC. | $46.55 | 2024-2025 | |
| Genzyme Corporation | $45.84 | 2024-2025 | |
| Genentech USA, INC. | $40.68 | 2024-2025 | Phesgo, Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $40.28 | 2023 | |
| Adc Therapeutics America, INC. | $40.28 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $38.32 | 2025 | Ultomiris |
| Springworks Therapeutics, INC. | $27.44 | 2024 | Ogsiveo |
| Rigel Pharmaceuticals, INC. | $27.09 | 2024 | Rezlidhia, Tavalisse |
| Jazz Pharmaceuticals INC. | $26.39 | 2025 | |
| Iovance Biotherapeutics, INC. | $23.26 | 2025 | Amtagvi |
| Beigene USA, INC. | $20.92 | 2024 | Tevimbra |
| Geron Corporation | $19.86 | 2025 | Rytelo |
| Fennec Pharmaceuticals, INC. | $19.27 | 2025 | Fyarro |
| G1 Therapeutics, INC. | $19.05 | 2023 | Cosela |
| Sumitomo Pharma America, INC. | $18.69 | 2025 | Orgovyx |
| Karyopharm Therapeutics INC. | $17.69 | 2024 | Xpovio |
| Cycle Pharmaceuticals INC | $17.10 | 2025 | Phyrago |
| Stemline Therapeutics INC. | $16.26 | 2025 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.83 | 2024 | Gilotrif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dallas Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.